Gisondi P, Loconsole F, Raimondo P, Ravasio R. Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy. Grhta [Internet]. 2021 Sep. 6 [cited 2024 Apr. 24];8(1):120-3. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/2258